New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

Item
http://www.wikidata.org/entity/Q26800937
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.An Update on Medical Treatment Options for Hidradenitis Suppurativa.Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.The epidemiology of childhood psoriasis: a scoping review.Unmet Needs and Future Directions in Inflammatory Eye Disease.Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice.IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report.Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.Targeting IL-23 in psoriasis: current perspectives.Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
P2860

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

Item
http://www.wikidata.org/entity/Q26800937
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@ast
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@en
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@nl
type
label
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@ast
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@en
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@nl
prefLabel
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@ast
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@en
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@nl
P1433
P1476
P2093
P275
P2860
P304
P31
P356
P407
P433
P478
P5008
P577
P5875
P698
P921
P932
P356
P1433
P1476
New and emerging biologic ther ...... for IL-17 and IL-23 inhibitors
@en
P2093
P275
P2860
P304
P31
P356
P407
P433
P478
P5008
P577
P5875
P698
P921
P932